{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:05:40Z","timestamp":1771553140431,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the efficacy of peficitinib in reducing joint damage and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis used data from a placebo-controlled, phase 3 trial (RAJ4) of peficitinib in patients with rheumatoid arthritis and inadequate response to methotrexate. Erosion and joint space narrowing (JSN) were assessed at baseline and at Week 28\/early termination of treatment using the van der Heijde-modified Sharp method. A univariate logistic regression analysis of change from baseline in a modified total Sharp score identified predictive factors with significant treatment interaction; the effects of these factors on treatment response were further evaluated using a multivariate model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analyses included 481 patients. For most joint groups, peficitinib demonstrated a reduced change from baseline at Week 28\/early termination in erosion and JSN scores versus placebo; a numerically greater effect was observed with peficitinib 150\u2009mg versus 100\u2009mg. Baseline C-reactive protein (CRP) and prednisolone dose were identified as clinically significant negative predictive factors: the treatment effect decreased as CRP or prednisolone dose increased for both peficitinib doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Peficitinib 100\u2009mg and 150\u2009mg reduced joint damage versus placebo, across almost all joint groups. Higher baseline CRP and\/or prednisolone dose were associated with reduced peficitinib efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                  <jats:p>NCT02305849<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac021","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T15:05:31Z","timestamp":1646924731000},"page":"73-80","source":"Crossref","is-referenced-by-count":6,"title":["<i>Post hoc<\/i> analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Corporate Strategy Department , Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Biostatistics Group , Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musashi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Japan-Asia Clinical Development 1 , Development, Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-7146","authenticated-orcid":false,"given":"Mitsuhiro","family":"Rokuda","sequence":"additional","affiliation":[{"name":"Medical Science, Medical Affairs Japan , Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"2023011210564595300_R1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000662","article-title":"Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"2023011210564595300_R2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/1529-0131(200009)43:9<1927::AID-ANR3>3.0.CO;2-B","article-title":"The course of radiologic damage during the first six years of rheumatoid arthritis","volume":"43","author":"Hulsmans","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023011210564595300_R3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/14397595.2019.1703484","article-title":"Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: analysis of data from the DRIVE and DESIRABLE studies","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023011210564595300_R5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/s10165-012-0742-6","article-title":"A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis","volume":"23","author":"Takeuchi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/14397595.2013.843764","article-title":"Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial","volume":"24","author":"Yamamoto","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023011210564595300_R8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210564595300_R9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2023011210564595300_R11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023011210564595300_R12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R13","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"2023011210564595300_R14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2023011210564595300_R15","article-title":"Smyraf Tablets\u00ae 50 mg and 100 mg: Deliberation Report","author":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan","year":"2019"},{"key":"2023011210564595300_R16","article-title":"Smyraf Film-Coated Tablets 50mg","author":"Food and Drug Administration Taiwan"},{"key":"2023011210564595300_R17","article-title":"Smyraf Film-Coated Tablets 100mg","author":"Food and Drug Administration Taiwan"},{"key":"2023011210564595300_R18","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023011210564595300_R19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023011210564595300_R20","article-title":"Inhibition of joint destruction in patients with rheumatoid arthritis treated with peficitinib in combination with methotrexate: a randomized, double-blind, placebo-controlled trial in Japan","volume-title":"Arthritis Rheumatol","author":"Takeuchi"},{"key":"2023011210564595300_R21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2023011210564595300_R22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis","volume":"35","author":"van der Heijde","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2023011210564595300_R23","article-title":"Overview of Methods for Subgroup and Biomarker Identification From Clinical Data","author":"Lipkovich","year":"2018"},{"key":"2023011210564595300_R24","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1106-y","article-title":"Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials","volume":"18","author":"Landew\u00e9","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023011210564595300_R25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14397595.2020.1805142","article-title":"Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023011210564595300_R26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","article-title":"Therapeutic criteria in rheumatoid arthritis","volume":"140","author":"Steinbrocker","year":"1949","journal-title":"J Am Med Assoc"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac021\/43231142\/roac021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/73\/48626471\/roac021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/73\/48626471\/roac021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:05:00Z","timestamp":1673525100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/73\/6546423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac021","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,3,10]]}}}